SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations

SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of a...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 5171 - 11
Main Authors Hederman, Andrew P., Natarajan, Harini, Heyndrickx, Leo, Ariën, Kevin K., Wiener, Joshua A., Wright, Peter F., Bloch, Evan M., Tobian, Aaron A. R., Redd, Andrew D., Blankson, Joel N., Rottenstreich, Amihai, Zarbiv, Gila, Wolf, Dana, Goetghebuer, Tessa, Marchant, Arnaud, Ackerman, Margaret E.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 24.08.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text
ISSN2041-1723
2041-1723
DOI10.1038/s41467-023-40960-0

Cover

More Information
Summary:SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve. As the SARS-SoV-2 pandemic progressed and the vaccinated population increased, a number of variants of concerns that circumvented the vaccine induced immunity emerged. Here the authors compare SARS-SoV-2 mRNA vaccine responses in pregnant women and other people, characterising the antibody response and Fc functions, and potency against a range of variants of concern.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-40960-0